SUPERSTRING CAPITAL MANAGEMENT LP Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001931118

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 32 positions · Total reported value $158.38M · Top-10 concentration 63.8% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 65.1% · 8 new · 9 cut · 11 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +26.6% · vs SPY +11.8% · Prev Value $139.97M — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, SUPERSTRING CAPITAL MANAGEMENT LP disclosed 32 equity positions with a combined reported value of $158.38M. The filing implies a focused portfolio: its ten largest positions account for 63.8% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were COGT ($13.29M), AXSM ($13.20M), GMAB ($11.83M). By sector, the heaviest allocations are Health Care 99.8%, Other 0.2%.

Versus the prior quarter, SUPERSTRING CAPITAL MANAGEMENT LP opened 8 new positions, trimmed 9 and fully exited 11, a turnover rate of 65.1% of positions. The portfolio's overlap with the prior quarter was 56% of names.

The largest new positions opened in Q2 2026 were RVMD ($9.56M), ONC ($3.50M), HELP ($1.35M).

Of the 11 positions fully exited versus the prior quarter, the largest were SMMT ($16.93M), VRTX ($4.92M), IQV ($4.38M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • RVMD REVOLUTION MEDICINES INC COM · $9.56M
  • ONC BEONE MEDICINES LTD · $3.50M
  • HELP CYBIN INC · $1.35M
  • KNSA KINIKSA PHARMACEUTICALS INTE · $1.21M
  • ROIV ROIVANT SCIENCES LTD F · $906.80K
  • FTH FAETH THERAPEUTICS INC · $354.38K
  • BOLD BOUNDLESS BIO INC · $138.39K
  • VYNE VYNE THERAPEUTICS INC · $39.87K

Fully Exited (vs previous quarter)

  • SMMT SUMMIT THERAPEUTICS INC · prev qtr: $16.93M
  • VRTX VERTEX PHARMACEUTICALS INC COM · prev qtr: $4.92M
  • IQV IQVIA HLDGS INC · prev qtr: $4.38M
  • ARVN ARVINAS INC · prev qtr: $3.31M
  • ORKA ORUKA THERAPEUTICS INC · prev qtr: $3.12M
  • TVTX TRAVERE THERAPEUTICS INC · prev qtr: $3.05M
  • PFE PFIZER INC · prev qtr: $2.08M
  • TSHA TAYSHA GENE THERAPIES INC · prev qtr: $1.15M

Insider Transactions (Form 4)

Latest SUPERSTRING CAPITAL MANAGEMENT LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Superstring Capital Management, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 32 positions worth $158.38M in total. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-118766 (status: Approved), registered 2020-05-20
  • Regulatory AUM (Form ADV): $339.50M as of 2026-03-30
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 1 hedge funds
  • Website: superstringcap.com

Portfolio Structure

  • 32 positions · $158.38M reported value (Q2 2026)
  • Top 10 holdings = 63.8% of reported value
  • Largest position: COGT (COGENT BIOSCIENCES INC) at 8.4%
  • Average position size: $4.95M

Sector Tilt

  • Health Care 99.8%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 8 new, 12 added, 9 reduced, 11 exited
  • 3 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to be bullish on the Health Care sector, as evidenced by the significant additions to healthcare stocks and a reduction in exposure to a healthcare stock that was previously held. This suggests a positive outlook on the healthcare sector, possibly driven by expectations of growth in biotechnology and pharmaceuticals. 2. Key Moves: - Added: The fund added significant positions in COGT, AXSM, GMAB, CLDX, TRVI, RVMD, and VIR, indicating a focus on potentially high-growth biotech and pharmaceutical companies. - Reduced: The fund reduced positions in DFTX, IMVT, and URGN, possibly due to a reassessment of these companies' prospects or a shift in strategy. 3. Portfolio Structure: - Passive/Active: The portfolio seems to be active, as the fund is actively adding and reducing positions, indicating a proactive management style. - Sector Bias: There is a strong bias towards the Health Care sector, particularly within biotechnology and pharmaceuticals. - Risk Appetite: The fund shows a higher risk appetite, as it is investing in potentially high-growth, high-risk biotech and pharmaceutical companies. 4. Per-Holding One-Liner: - COGT: Cogent Biosciences Inc. (Biotechnology) - AXSM: Axsome Therapeutics Inc. (Biotechnology) - GMAB: Genmab A/S (Biotechnology) - CLDX: Celldex Therapeutics Inc. (Biotechnology) - TRVI: Trevi Therapeutics Inc. (Biotechnology) - RVMD: Revolution Medicines Inc. (Biotechnology) - DFTX: Definium Therapeutics Inc. (Biotechnology) - VIR: Vir Biotechnology Inc. (Biotechnology) - IMVT: Immunovant Inc. (Biotechnology) - URGN: Urogen Pharma Ltd. (Pharmaceuticals) 5. One-Sentence Style Summary: SUPERSTRING CAPITAL MANAGEMENT LP's 2026-Q2 rebalancing reflects a strategic shift towards high-growth biotech and pharmaceutical companies, indicating a positive outlook on the healthcare sector with a proactive, active management approach.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 99.8%
Other 0.2%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 343.28K $13.29M 8.39%
8.39%
Add
2 53.92K $13.20M 8.33%
8.33%
Add
3 430.60K $11.83M 7.47%
7.47%
Add
4 287.58K $10.70M 6.76%
6.76%
Add
5 524.22K $9.78M 6.17%
6.17%
Add
6 51.05K $9.56M 6.04%
6.04%
New
7 188.28K $8.86M 5.59%
5.59%
Reduce
8 853.68K $8.70M 5.49%
5.49%
Add
9 208.37K $8.03M 5.07%
5.07%
Reduce
10 191.31K $7.04M 4.45%
4.45%
Reduce
11 521.08K $6.79M 4.29%
4.29%
Add
12 552.50K $6.35M 4.01%
4.01%
Add
13 977.46K $6.02M 3.80%
3.80%
Reduce
14 125.43K $4.50M 2.84%
2.84%
Reduce
15 406.08K $4.40M 2.78%
2.78%
Add
16 7.17K $3.89M 2.45%
2.45%
Add
17 66.79K $3.88M 2.45%
2.45%
Reduce
18 12.27K $3.50M 2.21%
2.21%
New
19 1.28M $3.48M 2.20%
2.20%
Add
20 155.81K $2.96M 1.87%
1.87%
Reduce
21 63.16K $2.78M 1.75%
1.75%
Reduce
22 30.46K $2.14M 1.35%
1.35%
Add
23 257.68K $1.36M 0.86%
0.86%
Reduce
24 204.42K $1.35M 0.85%
0.85%
New
25 18.87K $1.21M 0.76%
0.76%
New
26 25.62K $906.80K 0.57%
0.57%
New
27 63.65K $812.15K 0.51%
0.51%
Hold
28 121.46K $463.97K 0.29%
0.29%
Hold
29 14.18K $354.38K 0.22%
0.22%
New
30 55.36K $138.39K 0.09%
0.09%
New
31 250.00K $85.31K 0.05%
0.05%
Hold
32 61.27K $39.87K 0.03%
0.03%
New

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 70% R 70% F1 70% (modelled on 2026-Q1; 7/10 hit)

Low-confidence forecast This fund replaces about 50% of its Top-10 each quarter and backtests at F1 50% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (9 quarters)

Avg precision 50% · recall 50% · F1 50% · avg rank error 4.3 · Top-10 turnover 50%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q2 40% 40% 40% CYTK · NKTX · BBIO · SVRA · ETNB · IDYA · FATE · ROIV · DAWN · MRNS CYTK · LEGN · TERN · BBIO · ETNB · NKTX · ZLAB · KROS · ACLX · ARWR
2024-Q3 30% 30% 30% CYTK · LEGN · TERN · NKTX · BBIO · ETNB · ZLAB · KROS · ACLX · ARWR CYTK · TERN · GPCR · ORIC · TIL · NVCR · BBIO · FATE · CAPR · TNGX
2024-Q4 50% 50% 50% TERN · CYTK · GPCR · ORIC · TIL · NVCR · FATE · BBIO · TNGX · CAPR TERN · ZLAB · NVCR · BBIO · COGT · CYTK · GPCR · IDYA · URGN · SMMT
2025-Q1 50% 50% 50% TERN · ZLAB · NVCR · BBIO · COGT · CYTK · IDYA · GPCR · URGN · TIL ZLAB · BBIO · VRNA · LEGN · PFE · URGN · COGT · ORIC · TVTX · TERN
2025-Q2 60% 60% 60% ZLAB · VRNA · BBIO · LEGN · ORIC · PFE · URGN · COGT · TVTX · TERN COGT · VRNA · NBIX · TERN · RARE · ZLAB · JAZZ · BBIO · TVTX · IONS
2025-Q3 50% 50% 50% COGT · VRNA · NBIX · RARE · JAZZ · TERN · ZLAB · TVTX · ORIC · BBIO ZLAB · CDTX · TERN · ETNB · IMVT · JAZZ · COGT · SVRA · BBIO · SMMT
2025-Q4 50% 50% 50% ZLAB · CDTX · ETNB · IMVT · TERN · JAZZ · COGT · SVRA · BBIO · SMMT CDTX · TERN · URGN · COGT · DVAX · SION · IMVT · AXSM · SVRA · MNMD
2026-Q1 50% 50% 50% CDTX · URGN · TERN · COGT · IMVT · DVAX · AXSM · SION · TSHA · SVRA SMMT · IMVT · COGT · SVRA · URGN · DFTX · VIR · PCVX · CLDX · SION
2026-Q2 ★ 70% 70% 70% SMMT · SVRA · IMVT · COGT · URGN · VIR · PCVX · DFTX · CLDX · GMAB COGT · AXSM · GMAB · CLDX · TRVI · RVMD · DFTX · VIR · IMVT · URGN

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did SUPERSTRING CAPITAL MANAGEMENT LP buy in 2026-Q2?

In its 2026-Q2 13F filing, SUPERSTRING CAPITAL MANAGEMENT LP reported 32 equity positions worth $158.38M in aggregate; its largest disclosed positions were COGT ($13.29M), AXSM ($13.20M), GMAB ($11.83M).

How large is SUPERSTRING CAPITAL MANAGEMENT LP's portfolio?

SUPERSTRING CAPITAL MANAGEMENT LP reported $158.38M of long equity holdings across 32 positions as of 2026-Q2. Top-10 holdings account for 63.8% of reported value.

What is SUPERSTRING CAPITAL MANAGEMENT LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/superstring-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →